Prescription medication · Uricosuric Agent
probenecid
Also sold as Benemid.
Data updated 2026-05-15
- 1,152
- FDA reportsRarely reported
- 37
- InteractionsSeveral interactions
- $0.87
- Generic price (NADAC)
What the data shows
probenecid (Benemid) is a prescription Uricosuric Agent, among the least-reported drugs the FDA tracks (1,152 FDA reports), with 37 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.87/unit
Generic Available
Yes (6 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Information not available.
Common side effects
Diarrhea, Nausea, Yeast infection of the vagina
Key warnings
No specific warnings noted. Always follow your prescriber's instructions.
Side Effects (from patient reports)
Based on 1,152 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for probenecid, by number of reports
- Diarrhea
Diarrhea
76 reports
- Difficulty breathing
Difficulty breathing
52 reports
- Adenovirus infection
Adenovirus infection
47 reports
- Weakness
Weakness
47 reports
- Tiredness
Tiredness
46 reports
- Nausea
Nausea
41 reports
- Pain
Pain
41 reports
- Dizziness
Dizziness
39 reports
- Pneumonia
Pneumonia
39 reports
- Kidney failure
Kidney failure
37 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for probenecid each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where probenecid sits
probenecid has more FDA adverse-event reports than 7% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is probenecid; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,152 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
1,152
Reports Mentioning Death
163
14.1% of reports — not proof of cause
Hospitalization Reports
396
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | DIARRHOEA | 76 |
| 4 | DYSPNOEA | 52 |
| 5 | ADENOVIRUS INFECTION | 47 |
| 6 | ASTHENIA | 47 |
| 7 | FATIGUE | 46 |
| 8 | NAUSEA | 41 |
| 9 | PAIN | 41 |
| 10 | DIZZINESS | 39 |
| 11 | PNEUMONIA | 39 |
| 12 | RENAL FAILURE | 37 |
| 13 | ACUTE KIDNEY INJURY | 36 |
| 14 | VOMITING | 36 |
| 15 | DEATH | 35 |
| 16 | HEADACHE | 33 |
| 17 | PYREXIA | 33 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Known Drug Interactions
Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.
Mechanism: Probenecid slows down the body's ability to clear ketorolac, which leads to much higher and potentially unsafe levels of the drug in your system.
What to do: These two medicines should not be used together.
7.8 Probenecid and Cimetidine No significant effect of probenecid or cimetidine on the Cmax of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t 1/2 of levofloxacin were higher while CL/F and CLR were lower during concomitant treatment of levofloxacin with probenecid or cimetidine compared to levofloxacin alone. However, these changes do not warrant dosage adjustment for levofloxacin when probenecid or cimetidine is co-administered.
Mechanism: Probenecid slows down the kidneys' ability to remove levofloxacin, which keeps the antibiotic in your system for a longer time.
What to do: No dose changes are usually needed, but your doctor will monitor your progress.
7 DRUG INTERACTIONS Co‑administration with probenecid is not recommended. ( 7.4 ) 7.1 Probenecid Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Co-administration of probenecid is not recommended.
Mechanism: Probenecid blocks the kidneys from removing amoxicillin from the blood. This causes the antibiotic to stay in your body longer and reach higher levels than normal.
What to do: This combination is not recommended, and you should talk to your doctor about using a different treatment plan.
7 DRUG INTERACTIONS Co‑administration with probenecid is not recommended. ( 7.4 ) 7.1 Probenecid Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Co-administration of probenecid is not recommended.
Mechanism: Probenecid slows down the kidneys from clearing amoxicillin out of your system, which can lead to higher levels of the drug in your body. It does not affect how the other part of the medicine, clavulanic acid, is removed.
What to do: This combination is not recommended by the manufacturer. Talk to your doctor about alternative treatments or necessary adjustments to your prescription.
7 DRUG INTERACTIONS 7.1 Probenecid In vitro , avibactam is a substrate of OAT1 and OAT3 transporters which might contribute to the active uptake from the blood compartment, and thereby its excretion. As a potent OAT inhibitor, probenecid inhibits OAT uptake of avibactam by 56% to 70% in vitro and, therefore, has the potential to decrease the elimination of avibactam when co-administered. Because a clinical interaction study of AVYCAZ or avibactam alone with probenecid has not been conducted, co-administration of AVYCAZ with probenecid is not recommended [ see Clinical Pharmacology ( 12.3 ) ] .
Mechanism: Probenecid blocks the body's ability to move the antibiotic out of the blood and into the urine. This causes the antibiotic levels to stay too high for too long.
What to do: This combination is not recommended. Talk to your doctor about using a different medication.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
What are the common side effects of probenecid?
Does probenecid interact with other medications?
What drug class is probenecid?
Related Medications in Uricosuric Agent
Other drugs grouped near probenecid - same-class peers and common alternatives.
abatacept
Orencia
Orencia is a medicine that helps to reduce inflammation.
Compare with probenecid →
acetaminophen
Tylenol
Acetaminophen (Tylenol) is a medicine that can relieve pain and reduce fever.
Compare with probenecid →
acetaminophen/hydrocodone
Vicodin, Norco
This medicine contains acetaminophen and hydrocodone.
Compare with probenecid →
acetaminophen/oxycodone
Percocet
Percocet is a strong pain medicine.
Compare with probenecid →
adalimumab
Humira
Idacio is a medicine that blocks a protein called TNF.
Compare with probenecid →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on probenecid
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for probenecid
The FDA label for probenecid (sold under brand names such as Benemid) classifies it as a prescription-only medication in the Uricosuric Agent class. Regulatory labeling describes its approved uses and the patient populations studied in pre-market trials. Official labeling lists 5 commonly reported side effects, including Diarrhea, Nausea, Yeast infection of the vagina.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,152 voluntary reports. The database also lists 37 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS shows a generic unit cost of $0.87.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: December 6, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages